Acute ischemic stroke
Conditions
Interventions
Experimental group1:Standard dose alteplase
Experimental group2:low-dose alteplase
Sponsors
Xianyang Hospital of Yan 'an University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 80 years; 2. The clinical symptoms are consistent with the diagnosis of ischemic stroke; 3. The time from onset to randomization is within 4.5 hours; 4. National Institutes of Health Stroke Scale (NIHSS) score 4-25; 5. CT scan indicates that the early signs of cerebral infarction are negative; 6. Cranial CT was used to evaluate leukoaraiosis, the modified Van Swieten Scale score was >=1 point, and it was decided to undergo intravenous alteplase thrombolysis; 7. Patients or their families signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. With evidence of active internal hemorrhage or trauma fracture, intracranial hemorrhage cannot be excluded, including suspected subarachnoid hemorrhage; 2. Very slight or rapid improvement of neurological dysfunction; 3. mRS score >= 2 points before the onset; 4. The time of onset cannot be determined, and the maximum possible time from onset to the start of thrombolytic therapy exceeds 4.5 hours; 5. Neurological deficits are considered to be caused by epileptic seizures; 6. History of intracranial hemorrhage, arteriovenous malformation or intracranial aneurysm; 7. A history of intracranial surgery, head trauma or symptomatic ischemic stroke within the last 3 months, a history of surgery within the last 14 days, and a history of lumbar puncture or arterial puncture that is not suitable for hemostasis in the last 7 days; 8. Pregnancy; 9. Significant bleeding risk, platelet count 1.5; 10. Blood sugar 185mmHg or diastolic blood pressure >110mmHg before thrombolytic therapy; 12. CT has shown early cerebral infarction with low density > 1/3 of the middle cerebral artery blood supply area; 13. Accept endovascular interventional therapy; 14. Patients with chronic hemodialysis and severe renal insufficiency (glomerular filtration rate 220umol/L (2.5mg/dl)); 15. Patients with malignant tumors and patients undergoing chemotherapy; 16. The life expectancy of any advanced disease is less than 6 months; 17. Not expected to complete follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Modified Rankin Scale score;Incidence of intracranial hemorrhage;mortality rate; | — |
Countries
China
Contacts
Public ContactXu Jiaping
Xianyang Hospital of Yan 'an University
Outcome results
None listed